Hyponatremia and Cancer: From Bedside to Benchside

8Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

Hyponatremia is the most common electrolyte disorder encountered in hospitalized patients. This applies also to cancer patients. Multiple causes can lead to hyponatremia, but most frequently this electrolyte disorder is due to the syndrome of inappropriate antidiuresis. In cancer patients, this syndrome is mostly secondary to ectopic secretion of arginine vasopressin by tumoral cells. In addition, several chemotherapeutic drugs induce the release of arginine vasopressin by the hypothalamus. There is evidence that hyponatremia is associated to a more negative outcome in several pathologies, including cancer. Many studies have demonstrated that in different cancer types, both progression-free survival and overall survival are negatively affected by hyponatremia, whereas the correction of serum [Na+] has a positive effect on patient outcome. In vitro studies have shown that cells grown in low [Na+] have a greater proliferation rate and motility, due to a dysregulation in intracellular signalling pathways. Noteworthy, vasopressin receptors antagonists, which were approved more than a decade ago for the treatment of euvolemic and hypervolemic hyponatremia, have shown unexpected antiproliferative effects. Because of this property, vaptans were also approved for the treatment of polycystic kidney disease. In vitro evidence indicated that this family of drugs effectively counteracts proliferation and invasivity of cancer cells, thus possibly opening a new scenario among the pharmacological strategies to treat cancer.

References Powered by Scopus

COVID-19: consider cytokine storm syndromes and immunosuppression

7223Citations
N/AReaders
Get full text

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

3627Citations
N/AReaders
Get full text

Oxyradicals and DNA damage

1682Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hyponatremia Promotes Cancer Growth in a Murine Xenograft Model of Neuroblastoma

3Citations
N/AReaders
Get full text

Associations between serum sodium level ranges with geriatric syndromes

1Citations
N/AReaders
Get full text

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fibbi, B., Marroncini, G., Naldi, L., Anceschi, C., Errico, A., Norello, D., & Peri, A. (2023, February 1). Hyponatremia and Cancer: From Bedside to Benchside. Cancers. MDPI. https://doi.org/10.3390/cancers15041197

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

33%

Researcher 2

33%

Professor / Associate Prof. 1

17%

Lecturer / Post doc 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

75%

Design 1

13%

Biochemistry, Genetics and Molecular Bi... 1

13%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1
Social Media
Shares, Likes & Comments: 3

Save time finding and organizing research with Mendeley

Sign up for free